Related Experiment Videos
Thiazolidinediones and slowing the progression of diabetes
Timothy Jackson1, Anthony Aquilina, John Bloom
1Section of Endocrinology/Metabolism, West Virginia University, Morgantown, West Virginia, USA.
Abstract:
A continuing goal of treatment of diabetes is to slow the progression of the disease through the preservation of beta-cell function. To assess efficacious and cost-effective methods of doing this, The Pharmacy & Therapeutics Society (Glastonbury, CT) assembled a study group of health plan medical directors. Based on a review of the data, the group studied the value of earlier diagnosis and the administration of thiazolidinediones. The potential role for health plans to support this approach to diabetes care is outlined below.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Antihypertensive Drugs: Thiazide-Class Diuretics
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...